NCT03455270: G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have ER+ tumor(s)
Exclusions: Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease

Comments are closed.

Up ↑